JP7478227B2 - 細胞老化抑制剤、生体組織修復促進剤、遺伝子発現調節剤及び製造方法 - Google Patents

細胞老化抑制剤、生体組織修復促進剤、遺伝子発現調節剤及び製造方法 Download PDF

Info

Publication number
JP7478227B2
JP7478227B2 JP2022511936A JP2022511936A JP7478227B2 JP 7478227 B2 JP7478227 B2 JP 7478227B2 JP 2022511936 A JP2022511936 A JP 2022511936A JP 2022511936 A JP2022511936 A JP 2022511936A JP 7478227 B2 JP7478227 B2 JP 7478227B2
Authority
JP
Japan
Prior art keywords
gene
extracellular vesicles
biological tissue
promoting
tissue repair
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022511936A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2021200299A5 (cg-RX-API-DMAC7.html
JPWO2021200299A1 (cg-RX-API-DMAC7.html
Inventor
貴将 石止
昌之 山根
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujifilm Corp
Original Assignee
Fujifilm Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujifilm Corp filed Critical Fujifilm Corp
Publication of JPWO2021200299A1 publication Critical patent/JPWO2021200299A1/ja
Publication of JPWO2021200299A5 publication Critical patent/JPWO2021200299A5/ja
Application granted granted Critical
Publication of JP7478227B2 publication Critical patent/JP7478227B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2022511936A 2020-03-31 2021-03-19 細胞老化抑制剤、生体組織修復促進剤、遺伝子発現調節剤及び製造方法 Active JP7478227B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020065052 2020-03-31
JP2020065052 2020-03-31
PCT/JP2021/011546 WO2021200299A1 (ja) 2020-03-31 2021-03-19 細胞老化抑制剤、生体組織修復促進剤、遺伝子発現調節剤及び製造方法

Publications (3)

Publication Number Publication Date
JPWO2021200299A1 JPWO2021200299A1 (cg-RX-API-DMAC7.html) 2021-10-07
JPWO2021200299A5 JPWO2021200299A5 (cg-RX-API-DMAC7.html) 2022-11-15
JP7478227B2 true JP7478227B2 (ja) 2024-05-02

Family

ID=77928040

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022511936A Active JP7478227B2 (ja) 2020-03-31 2021-03-19 細胞老化抑制剤、生体組織修復促進剤、遺伝子発現調節剤及び製造方法

Country Status (3)

Country Link
JP (1) JP7478227B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220148883A (cg-RX-API-DMAC7.html)
WO (1) WO2021200299A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7371975B1 (ja) * 2022-09-27 2023-10-31 セルソース株式会社 細胞外小胞の製造方法及び細胞外小胞含有組成物
JP7433685B1 (ja) 2023-06-09 2024-02-20 日生バイオ株式会社 真皮線維芽細胞の機能賦活用剤及びそれを含んでなる化粧品

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016088689A1 (ja) 2014-12-05 2016-06-09 和光純薬工業株式会社 Timタンパク質結合担体、当該担体を用いた細胞外膜小胞及びウイルスの取得方法、除去方法、検出方法並びに当該担体を含むキット
CN108392494A (zh) 2018-05-15 2018-08-14 江苏大学 人脐带间质干细胞分泌的exosome在制备修复皮肤紫外线损伤的药物中的应用
CN109172859A (zh) 2018-09-06 2019-01-11 上海长海医院 人干细胞来源外泌体复合外源性透明质酸在制备皮肤创面缺损修复药物或材料中的应用
CN110548001A (zh) 2019-09-06 2019-12-10 沈阳细胞治疗工程技术研发中心有限公司 一种含脐带间充质干细胞外泌体的修复抗衰护肤品

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016088689A1 (ja) 2014-12-05 2016-06-09 和光純薬工業株式会社 Timタンパク質結合担体、当該担体を用いた細胞外膜小胞及びウイルスの取得方法、除去方法、検出方法並びに当該担体を含むキット
CN108392494A (zh) 2018-05-15 2018-08-14 江苏大学 人脐带间质干细胞分泌的exosome在制备修复皮肤紫外线损伤的药物中的应用
CN109172859A (zh) 2018-09-06 2019-01-11 上海长海医院 人干细胞来源外泌体复合外源性透明质酸在制备皮肤创面缺损修复药物或材料中的应用
CN110548001A (zh) 2019-09-06 2019-12-10 沈阳细胞治疗工程技术研发中心有限公司 一种含脐带间充质干细胞外泌体的修复抗衰护肤品

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
DENG, M. et al.,Photochemical & Photobiological Sciences,2020年03月01日,Vol. 19, No. 3,pp. 406-414
KATSUDA, T. et al.,Proteomics,2013年,Vol. 13,pp. 1637-1653
KIM, Y-J. et al.,Biochemical and Biophysical Research Communications,2017年,Vol. 493,pp. 1102-1108
LIANG, Y-C. et al.,Journal of Cellular Physiology,2019年,Vol. 234,pp. 23243-23255
LIU, Z. et al.,Cell Death Discovery,2019年,Vol. 5, article number 79,pp. 1-7
SONG, Y. et al.,STEM CELLS,2017年,Vol. 35,pp. 1208-1221
WANG, L. et al.,SCIENTIFIC REPORTS,2017年,Vol. 7, article number 13321,pp. 1-12
ZHANG, J. et al.,Journal of Translational Medicine,2015年,Vol. 13, article number 49,pp. 1-14
ZHANG, S. et al.,Life Sciences,2020年02月06日,Vol. 246, article number 117401,pp. 1-12
ZULUETA, A. et al.,Cellular Signalling,2018年,Vol. 51,pp. 110-118
山根 昌之、石止 貴将,和光純薬時報,2020年10月,Vol. 88, No. 4,pp. 10-11
炎症,1990年,vol.10, no.1,p.9-16

Also Published As

Publication number Publication date
KR20220148883A (ko) 2022-11-07
WO2021200299A1 (ja) 2021-10-07
JPWO2021200299A1 (cg-RX-API-DMAC7.html) 2021-10-07

Similar Documents

Publication Publication Date Title
Yang et al. Exosomes and their bioengineering strategies in the cutaneous wound healing and related complications: current knowledge and future perspectives
AU2017202287B2 (en) Composition for differentiation induction of adipocyte containing stem cell-derived exosome, regeneration of adipose tissue, and skin whitening or wrinkle improvement
RU2735139C2 (ru) Полученные из лизата тромбоцитов человека внеклеточные везикулы для применения в медицине
EP3862009A1 (en) Composition for skin regeneration and wound healing, comprising induced exosomes
KR101655780B1 (ko) 클로날 중간엽 줄기세포를 포함하는, 아토피성 피부염 예방 또는 치료용 약학적 조성물
KR20190060651A (ko) 줄기세포 유래의 엑소좀을 유효성분으로 포함하는 조성물의 피부장벽 강화 내지 기능 개선 용도
US20220362290A1 (en) Anti-fibrosis agent and method of producing extracellular vesicle having anti-fibrosis action
KR20190003387A (ko) 줄기세포 유래의 엑소좀을 유효성분으로 포함하는 조성물의 가려움증 억제 또는 개선 용도
KR20190069277A (ko) 줄기세포 유래의 엑소좀 및/또는 세포외 소포체를 유효성분으로 포함하는 조성물의 민감성 피부 예방, 억제, 완화 또는 개선 용도
KR20190003399A (ko) 줄기세포 유래의 엑소좀을 유효성분으로 포함하는 조성물의 피부 섬유증 개선 용도
US20240139257A1 (en) Methods and compositions for alopecia treatment using fibroblasts and fibroblast-derived products
WO2021200299A1 (ja) 細胞老化抑制剤、生体組織修復促進剤、遺伝子発現調節剤及び製造方法
JP2023538109A (ja) 骨髄由来間葉系幹細胞からの微小胞を使用する処置の組成物及び方法
Chakraborty et al. Stem-cell therapy in dermatology–Challenges and opportunities
EP4257674A1 (en) Method for isolating and culturing cord blood stem cells expressing gdf-3 at high level, and use of gdf-3
EP3903793A1 (en) Pharmaceutical composition comprising clonal stem cell for prevention or treatment of atopic dermatitis
RU2710368C2 (ru) Способ получения и концентрирования микроРНК-содержащих экзосом мультипотентных мезенхимально-стромальных клеток для применения в косметических и лекарственных средствах для стимуляции регенеративных процессов и замедления процессов старения
US20230126684A1 (en) Anti-inflammatory agent and method of producing extracellular vesicle having anti-inflammatory action
EP4091671A1 (en) Angiogenic agent and production method for extracellular vesicles having angiogenic effect
KR102814578B1 (ko) 제대혈간세포 유래 엑소좀을 포함하는 창상 치료 또는 창상 치료 촉진용 조성물
EP4520341A1 (en) Composition for wound treatment comprising stem cell-derived extracellular vesicles with enhanced efficacy
Rosca et al. Mesenchymal stromal cells for wound healing therapy: From expectations to reality
KR102743932B1 (ko) 경막외 지방 중간엽 줄기세포 유래 엑소좀을 포함하는 골 질환 치료용 조성물
Muniandy et al. Proliferation rate and cell size analyses of human peripheral blood suspension stem cells from three culturing terms populations
WO2025027074A1 (en) Method for the polarization of cells to a new m2 phenotype and uses of said m2-polarized cells

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220914

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220921

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230808

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231005

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231219

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240219

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240402

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240419

R150 Certificate of patent or registration of utility model

Ref document number: 7478227

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313111

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350